Krouwer J S
Department of Evaluations and Reliability, Ciba Corning Diagnostics Corp, Medfield, Mass. 02052-1688.
Arch Pathol Lab Med. 1992 Jul;116(7):726-31.
The process of method evaluation starts with identifying goals either to demonstrate the clinical validity of an assay or to identify assay error sources that require improvement. Taguchi's idea of continual quality improvement vs the notion of meeting or failing specification has been applied to clinical chemistry. In this article, I propose a model of assay performance that includes the terms random interferences and protocol-specific biases (a series of systematic errors). I explain these terms, as well as the consequences of failing to consider them. To validate an assay clinically, I recommend direct estimation of total analytical error from a method comparison. To identify assay error sources that require improvement, I recommend a multifactor protocol (in addition to a method comparison). Individual error sources are related to total analytical error with the use of an error propagation technique. Much of the proposed data analysis techniques are straightforward but not routinely practiced. I demonstrate principles with the use of a cholesterol assay.
方法评估过程始于确定目标,要么是证明一种检测方法的临床有效性,要么是识别需要改进的检测误差来源。田口玄一的持续质量改进理念与达到或未达到规格标准的概念已应用于临床化学领域。在本文中,我提出了一种检测性能模型,其中包括随机干扰和特定方案偏差(一系列系统误差)等术语。我将解释这些术语以及未考虑它们的后果。为了在临床上验证一种检测方法,我建议通过方法比较直接估计总分析误差。为了识别需要改进的检测误差来源,我建议采用多因素方案(除了方法比较之外)。使用误差传播技术将各个误差来源与总分析误差相关联。本文提出的许多数据分析技术很简单,但并未常规应用。我将通过胆固醇检测来阐述相关原理。